# Angel M Garcia-Lora

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 48 papers | 2,419 citations | 236833 25 h-index | 289141 40 g-index |
| 50 all docs | 50 docs citations | 50 times ranked | 3254 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | MHC heterogeneity and response of metastases to immunotherapy. Cancer and Metastasis Reviews, 2021, 40, 501-517. | 2.7 | 12 |
| 2 | Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine. Cancers, 2020, 12, 1563. | 1.7 | 12 |
| 3 | MHC Class I Molecules and Cancer Progression: Lessons Learned from Preclinical Mouse Models. , 2020, , 189-204. | | 1 |
| 4 | MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy. Frontiers in Immunology, 2018, 9, 102. | 2.2 | 25 |
| 5 | Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab. Frontiers in Pharmacology, 2017, 8, 595. | 1.6 | 27 |
| 6 | Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. International Journal of Cancer, 2016, 138, 271-280. | 2.3 | 35 |
| 7 | MHC Class I Molecules and Cancer Progression: Lessons Learned from Preclinical Mouse Models. , 2015, , 161-175. | | 0 |
| 8 | Metastases in Immune-Mediated Dormancy: A New Opportunity for Targeting Cancer. Cancer Research, 2014, 74, 6750-6757. | 0.4 | 66 |
| 9 | A novel preclinical murine model of immune-mediated metastatic dormancy. OncoImmunology, 2014, 3, e29258. | 2.1 | 2 |
| 10 | Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. Pancreas, 2014, 43, 1066-1072. | 0.5 | 14 |
| 11 | Effect of thyroid hormoneâ€“nitric oxide interaction on tumor growth, angiogenesis, and aminopeptidase activity in mice. Tumor Biology, 2014, 35, 5519-5526. | 0.8 | 8 |
| 12 | T Lymphocytes Restrain Spontaneous Metastases in Permanent Dormancy. Cancer Research, 2014, 74, 1958-1968. | 0.4 | 53 |
| 13 | The pro-oxidant buthionine sulfoximine (BSO) reduces tumor growth of implanted Lewis lung carcinoma in mice associated with increased protein carbonyl, tubulin abundance, and aminopeptidase activity. Tumor Biology, 2014, 35, 7799-7805. | 0.8 | 2 |
| 14 | Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. Oncogene, 2014, 33, 3129-3139. | 2.6 | 31 |
| 15 | â€˜Hardâ€™ and â€˜softâ€™ loss of MHC class I expression in cancer cells. , 2014, , 63-78. | | 1 |
| 16 | HLA Class I Expression in Human Cancer. , 2013, , 13-30. | | 0 |
| 17 | MHC Class I Antigens In Malignant Cells. , 2013, , . | | 3 |
| 18 | MHC Class I Expression in Experimental Mouse Models of Cancer: Immunotherapy of Tumors with Different MHC-I Expression Patterns. , 2013, , 31-45. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286. | | 0 |
| 20 | Overview of MHC Class I Antigens. , 2013, , 1-11. | | 0 |
| 21 | MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis, 2012, 33, 687-693. | 1.3 | 69 |
| 22 | The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. Journal of Pathology, 2012, 227, 367-379. | 2.1 | 36 |
| 23 | Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunology, Immunotherapy, 2011, 60, 1257-1268. | 2.0 | 32 |
| 24 | Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunology, Immunotherapy, 2010, 59, 13-26. | 2.0 | 25 |
| 25 | The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible â€œhardâ€•lesions. Cancer Immunology, Immunotherapy, 2010, 59, 1601-1606. | 2.0 | 82 |
| 26 | HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunology, Immunotherapy, 2009, 58, 1507-1515. | 2.0 | 53 |
| 27 | Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunology, Immunotherapy, 2008, 57, 1727-1733. | 2.0 | 56 |
| 28 | The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer, 2008, 8, 78. | 1.1 | 75 |
| 29 | Role of Altered Expression of HLA Class I Molecules in Cancer Progression. Advances in Experimental Medicine and Biology, 2007, 601, 123-131. | 0.8 | 117 |
| 30 | MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189. | 6.2 | 128 |
| 31 | Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. International Journal of Cancer, 2007, 121, 2023-2030. | 2.3 | 12 |
| 32 | A new extract of the plant calendula officinalis produces a dual in vitroeffect: cytotoxic anti-tumor activity and lymphocyte activation. BMC Cancer, 2006, 6, 119. | 1.1 | 110 |
| 33 | Identification of the protein components of protein-bound polysaccharide (PSK) that interact with NKL cells. Cancer Immunology, Immunotherapy, 2005, 54, 395-399. | 2.0 | 9 |
| 34 | The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy, 2004, 53, 904-10. | 2.0 | 239 |
| 35 | Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunology, Immunotherapy, 2003, 52, 59-64. | 2.0 | 36 |
| 36 | Tumour immunology, vaccination and escape strategies. International Journal of Immunogenetics, 2003, 30, 177-183. | 1.2 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. International Journal of Cancer, 2003, 106, 521-527. | 2.3 | 79 |
| 38 | MHC class I antigens, immune surveillance, and tumor immune escape. Journal of Cellular Physiology, 2003, 195, 346-355. | 2.0 | 422 |
| 39 | Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene. British Journal of Cancer, 2003, 89, 192-198. | 2.9 | 28 |
| 40 | Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunology, Immunotherapy, 2001, 49, 621-628. | 2.0 | 45 |
| 41 | Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunology, Immunotherapy, 2001, 50, 191-198. | 2.0 | 23 |
| 42 | Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. International Journal of Cancer, 2001, 91, 109-119. | 2.3 | 78 |
| 43 | Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. Cancer Immunology, Immunotherapy, 2000, 48, 684-690. | 2.0 | 21 |
| 44 | Differential effect on U937 cell differentiation by targeting transcriptional factors implicated in tissue- or stage-specific induced integrin expression. Experimental Hematology, 1999, 27, 353-364. | 0.2 | 37 |
| 45 | Expression of HLA G in human tumors is not a frequent event. , 1999, 81, 512-518. | | 65 |
| 46 | Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. , 1999, 83, 91-97. | | 104 |
| 47 | Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunology, Immunotherapy, 1998, 47, 113-120. | 2.0 | 62 |
| 48 | Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine. Vaccine, 1994, 12, 585-591. | 1.7 | 26 |